In March, LI AUTO-W(02015) delivered 41,053 new vehicles, a year-on-year increase of 11.94%.
Ideal car - W (02015) announced that in March 2026, Ideal car delivered 41,053 new cars, an increase of 11.94% compared to the previous year. As of March 31, 2026, Ideal car's cumulative delivery volume reached 1,635,357 units.
LI AUTO (02015) announced that in March 2026, Ideacar delivered 41,053 new vehicles, an increase of 11.94% compared to the same period last year. As of March 31, 2026, Ideacar's historical cumulative delivery volume reached 1,635,357 vehicles.
With the resolution of production capacity bottlenecks, the delivery volume of Ideacar i6 exceeded 24,000 vehicles in March. The next-generation Ideacar L9 is expected to be launched in the second quarter of 2026. In March, the company unveiled the next-generation autonomous driving basic model MindVLA and 3D ViT three-dimensional visual encoder at the 2026 GTC conference, hosted by NVIDIA, which can directly perceive the real three-dimensional physical world, uniformly understand the geometry and semantics of real physical space, and align with human intelligence in spatial understanding.
As of March 31, 2026, Ideacar has 517 retail centers nationwide, covering 160 cities; 552 after-sales service centers and authorized service centers, covering 223 cities. Ideacar has deployed 4,057 Ideacar supercharging stations nationwide, with 22,439 charging piles.
Related Articles

BINHAI INV (02886) spent approximately HK$351,700 to repurchase 314,000 shares on April 1st.

AIA (01299) spent 201 million Hong Kong dollars to repurchase 2.292 million shares on April 1st.

Biocytogen Pharmaceuticals-B(02315) has reached a strategic cooperation with SIHUAN PHARM(00460) to accelerate research and development of innovative drugs in multiple areas such as weight loss.
BINHAI INV (02886) spent approximately HK$351,700 to repurchase 314,000 shares on April 1st.

AIA (01299) spent 201 million Hong Kong dollars to repurchase 2.292 million shares on April 1st.

Biocytogen Pharmaceuticals-B(02315) has reached a strategic cooperation with SIHUAN PHARM(00460) to accelerate research and development of innovative drugs in multiple areas such as weight loss.






